If you have priced Zepbound (tirzepatide) recently, you have probably noticed the number on the pharmacy receipt and the number Eli Lilly advertises rarely match. The list price sits above $1,000 a month, yet some people pay $25, others pay $349, and many pay somewhere in between. The gap comes down to how you buy it: through commercial insurance, with the manufacturer savings card, as a self-pay vial through LillyDirect, or at a retail pharmacy counter. This guide breaks down the real cost of Zepbound in 2026, dose by dose and channel by channel, so you can find the lowest legitimate price for your situation.
🔑 Key Takeaways
- The Zepbound list price is about $1,086 per month for a 28-day box of four single-dose pens, and that is what most cash-pay patients face at a retail counter before any discount.[5]
- With a commercial insurance plan that covers Zepbound, the manufacturer savings card can drop your copay to as little as $25 per fill, up to a $1,300 annual cap.[6]
- Self-pay vials and the KwikPen through LillyDirect run $299 a month for the 2.5 mg starting dose, $399 for 5 mg, and roughly $349 to $449 for higher doses, far below retail pen pricing.[3][6]
- GoodRx and other third-party coupons barely move the price on brand Zepbound because manufacturer contracts limit outside discounts, so the savings card and LillyDirect are the real levers.[7]
- Starting July 1, 2026, a temporary Medicare GLP-1 Bridge program will cover Zepbound for obesity at a $50 copay for many beneficiaries, the first broad Medicare access for weight-loss use.[9][10]
How much does Zepbound cost? The short answer
There is no single price for Zepbound. What you actually pay depends almost entirely on the channel you use. Here are the four prices worth memorizing for 2026:
- Retail list price: about $1,086 per 28-day supply of single-dose pens, the cash-pay default at most pharmacies.[5]
- With savings card and covered insurance: as little as $25 per month.[6]
- Self-pay vial / KwikPen through LillyDirect: $299 (2.5 mg) up to about $449 (higher doses), with promotional pricing as low as $349 for some higher-dose multi-dose pens.[3][6]
- Without coverage, using the savings card on pens: $499 per month.[6]
If you came here asking how much Zepbound costs per month, the honest answer is anywhere from $25 to $1,140 depending on those variables. The rest of this guide shows you exactly which number applies to you and how to land on the lowest one.
Zepbound list price and retail price in 2026
Zepbound's list price (the manufacturer's published wholesale-derived price, sometimes called the retail price) is approximately $1,086 for a one-month supply of single-dose pens. Eli Lilly received FDA approval for Zepbound for chronic weight management in adults with obesity, or overweight plus a weight-related condition, in November 2023, and the drug carries a second approval for moderate-to-severe obstructive sleep apnea in adults with obesity.[1][2][8]
At the pharmacy counter, the cash price tracks close to that list figure. Across major chains in 2026, a 28-day box of four pens generally runs:
| Pharmacy | Typical cash price (28-day pen box) |
|---|---|
| Costco / Sam's Club | ~$1,020 to $1,075 |
| Walmart | ~$1,060 to $1,115 |
| Kroger | ~$1,055 to $1,120 |
| CVS / Walgreens / Target | ~$1,069 to $1,135 |
| Rite Aid | ~$1,080 to $1,140 |
Cash prices vary by location and change frequently; figures reflect representative 2026 ranges and the published list price.[5][7]
This is why the cost of Zepbound at Walmart and the cost of Zepbound at Walgreens come out roughly the same: for a brand-only drug with no generic, retail pharmacies have little room to compete on the sticker. The meaningful savings come from the manufacturer and from buying the vial form, not from shopping one chain against another.
Why the receipt rarely shows the list price
Very few people pay the full $1,086. If your insurance covers Zepbound, your plan negotiates a lower net price and you pay a copay. If it does not, the savings card or LillyDirect vial route usually beats the counter price by hundreds of dollars. The list price mostly matters as the starting point that discounts are measured against.
Zepbound cost with the savings card and coupons
The single biggest lever for insured patients is the official Zepbound Savings Card from Eli Lilly. How much it saves depends on whether your commercial plan covers the drug:[6]
- Commercial insurance that covers Zepbound: you can pay as little as $25 for a 1-month, 2-month, or 3-month fill. Savings are capped at up to $150 per month and $1,300 per calendar year, so once you hit the annual cap your copay reverts to whatever your plan charges.
- Commercial insurance that does NOT cover Zepbound: the savings card brings single-dose pens down to $499 per month, a roughly $500 discount off list.
The hard limit: the savings card excludes anyone enrolled in a government program, including Medicare, Medicare Part D, Medicare Advantage, Medicaid, VA, TRICARE, and DoD coverage. If that describes you, the card is off the table and your best routes are the self-pay vial or, starting mid-2026, the new Medicare bridge program covered below.[6]
Do GoodRx, SingleCare, or other coupons help?
For most brand GLP-1 drugs, third-party discount cards deliver disappointing savings. GoodRx and SingleCare coupon prices on Zepbound generally land within a few percent of the cash price, because manufacturer contracts restrict how much outside programs can discount a brand-name, no-generic medication.[7] A coupon is worth a quick check, but do not expect it to compete with the $25 savings-card copay or the $299 to $449 LillyDirect vials. For self-pay patients, the discount-for-Zepbound conversation is really a LillyDirect conversation.
Zepbound self-pay cost: LillyDirect vials and KwikPen
If you do not have coverage, or you want to skip insurance entirely, Eli Lilly sells lower-cost forms of Zepbound directly to patients through LillyDirect. These come as single-dose vials (drawn up with a syringe) and, more recently, a multi-dose KwikPen. The self-pay pricing for 2026 is the cheapest legitimate way to get brand Zepbound without insurance:[3][6]
| Dose | LillyDirect self-pay price (with timely refill) | Price without timely refill |
|---|---|---|
| 2.5 mg (0.5 mL) | $299 / month | $349 / month |
| 5 mg (0.5 mL) | $399 / month | $499 / month |
| 7.5 mg (0.5 mL) | $449 / month | $499 / month |
| 10 mg (0.5 mL) | $449 / month | $699 / month |
| 12.5 mg (0.5 mL) | $449 / month | $699 / month |
| 15 mg (0.5 mL) | $449 / month | $699 / month |
Promotional vial prices for 7.5 mg and higher require refilling within 45 days; missing that window resets you to the higher regular price.[3]
The catch worth flagging in bold: doses of 7.5 mg and up keep their lower price only if you refill within 45 days. Let the prescription lapse and the 10 mg, 12.5 mg, and 15 mg vials jump to $699. For the single-dose pen format, the self-pay price through the savings program is $499 per month.[6] For most people on a maintenance dose, the LillyDirect vial at roughly $349 to $449 is the lowest self-pay cost of Zepbound available in 2026.
Vial vs pen: the format decides the price
The vial and KwikPen are the same medicine as the single-dose pen, but at a fraction of retail. The trade-off is that vials require you to draw the dose into a syringe yourself rather than click a pre-filled pen. If you are comfortable with that step, you can cut your monthly cost by hundreds of dollars. If you want the convenience of a pen and have covered insurance, the savings-card route to $25 may still win.
Zepbound cost comparison: every payment path side by side
This is the table competitors usually skip. It puts every realistic 2026 payment path next to each other so you can spot your cheapest option at a glance. Figures are per month for a typical maintenance dose.
| Payment path | Monthly cost | Best for | Catch |
|---|---|---|---|
| Insurance + savings card (covered) | $25 | Commercial plan that covers Zepbound | $1,300/yr cap; resets after |
| Medicare GLP-1 Bridge (from Jul 2026) | $50 | Eligible Medicare Part D members | Temporary; BMI criteria apply |
| LillyDirect self-pay vial (2.5 mg) | $299 | Self-pay starters | Vial requires drawing dose |
| LillyDirect self-pay vial (higher dose) | $349 to $449 | Self-pay maintenance | 45-day refill to keep low price |
| Savings card, no coverage (pens) | $499 | Commercial plan that excludes Zepbound | Higher than vials |
| Retail cash price (pens) | ~$1,020 to $1,140 | No other option | The most expensive route |
Synthesized from Lilly pricing pages, CMS, and 2026 retail data.[3][5][6][9]
Which cheapest option fits you? A quick decision guide
Use this to find the lowest-cost path in under a minute:
| Your situation | Lowest-cost route in 2026 | Expected monthly cost |
|---|---|---|
| Commercial insurance that covers Zepbound | Savings card on covered fill | $25 (until annual cap) |
| Commercial insurance, Zepbound not covered | LillyDirect self-pay vial | $299 to $449 |
| No insurance, paying cash | LillyDirect self-pay vial | $299 to $449 |
| Want a pen, no coverage | Savings card self-pay pen | $499 |
| On Medicare, qualify by BMI/condition | Medicare GLP-1 Bridge (from Jul 1, 2026) | $50 |
| On Medicare, before July 2026 | LillyDirect self-pay vial (card excluded) | $299 to $449 |
Why is Zepbound so expensive? Myth vs fact
"Why is Zepbound so expensive" is one of the most-searched cost questions, and a lot of the common explanations are wrong. Here is what actually drives the price.
| Common belief | The reality |
|---|---|
| "It costs that much to make." | Manufacturing cost is a small fraction of the price. The list price reflects U.S. branded-drug pricing, R&D recovery, and rebate-heavy contracts with pharmacy benefit managers, not raw production cost. |
| "A generic will be out soon." | Tirzepatide is under patent for years. No FDA-approved generic Zepbound exists, which is the core reason retail competition cannot lower the price.[1] |
| "Coupons should cut it in half." | Third-party coupons barely move brand GLP-1 pricing because of manufacturer contract restrictions. The savings card and LillyDirect are the real discounts.[7] |
| "Insurance always covers it." | Many commercial and most government plans historically excluded weight-loss drugs. Coverage is expanding in 2026 but is far from universal.[9][10] |
| "The list price is what everyone pays." | Almost no one pays $1,086 if they use the savings card or LillyDirect vials. List price is a reference point, not the typical out-of-pocket.[5][6] |
Will Zepbound prices go down?
They already have, and more relief is scheduled for 2026. Eli Lilly has cut self-pay Zepbound pricing multiple times, and a 2025-2026 agreement between Lilly and the U.S. government is set to expand access further. Under that deal, a multi-dose pen is expected to be offered at $299 for the lowest dose, with higher doses up to $449, representing roughly a $50 cut to prior direct-to-patient prices and pricing closer to what European patients pay.[9]
The bigger near-term change is Medicare. Starting July 1, 2026, a temporary Medicare GLP-1 Bridge program will cover Zepbound and Wegovy for obesity at a $50 copay per fill for eligible Part D members, running through the end of 2027 ahead of a possible permanent program. Eligibility hinges on a BMI of 35 or higher, or 27 or higher with a qualifying condition such as heart disease or prediabetes.[9][10] Note that this $50 copay sits outside standard Part D, so it does not count toward your Part D deductible or out-of-pocket cap.[10]
Looking further out, oral obesity drugs and additional competition are expected to put downward pressure on injectable GLP-1 pricing over the next few years. For a wider view of what affordable options exist today across the whole drug class, see our guide to the cheapest GLP-1 options ranked.
How is Zepbound cost different from Mounjaro?
Zepbound and Mounjaro are the same molecule, tirzepatide, sold under different brands: Zepbound for weight management and sleep apnea, Mounjaro for type 2 diabetes. Pricing and savings programs differ by brand and indication. If diabetes is part of your picture, compare the two in our Zepbound vs Mounjaro guide and the dedicated Mounjaro coupon and savings card breakdown. The clinical results behind both are identical, since they share the dual GIP/GLP-1 mechanism described in our explainer on how Zepbound works.
Is Zepbound worth the cost? What you get for the price
Cost is only half the equation. In the phase 3 SURMOUNT-1 trial, adults with obesity or overweight (without diabetes) taking the 15 mg dose lost an average of about 20.9% of body weight versus placebo over 72 weeks, with average reductions reaching 22.5%, roughly 52 lb (24 kg). About 96% of participants on 15 mg achieved at least 5% weight loss, compared with 28% on placebo.[4] In SURMOUNT-2, which studied adults who also had type 2 diabetes, mean weight reduction reached 15.7% at the 15 mg dose.[4]
Those are among the largest reductions seen with any approved obesity medication to date, which is part of why demand, and therefore price pressure, has stayed high. For realistic week-by-week expectations and trial-backed timelines across the class, see our overview of GLP-1 weight loss results, and for the buying logistics specifically, our guide on getting a Zepbound online prescription.
Frequently Asked Questions
References
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound/tirzepatide), November 8, 2023.
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound), December 2024.
- Eli Lilly / LillyDirect. Authentic Zepbound (tirzepatide) self-pay vial and KwikPen pricing.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. PMID 35658024.
- Zepbound cost 2026: list price (~$1,086) and copay savings overview.
- Eli Lilly. Zepbound Savings Card and self-pay options (copay, eligibility, vial/pen pricing).
- GoodRx. Zepbound prices, coupons, and savings (third-party discount limits on brand GLP-1s).
- U.S. Food and Drug Administration. Zepbound obstructive sleep apnea indication.
- Eli Lilly. Lilly and U.S. government agree to expand access to obesity medicines, 2026.
- KFF. What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries, 2026.
